{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:44:55Z","timestamp":1758476695192},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,6,4]],"date-time":"2012-06-04T00:00:00Z","timestamp":1338768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s11906-012-0280-9","type":"journal-article","created":{"date-parts":[[2012,6,4]],"date-time":"2012-06-04T15:08:37Z","timestamp":1338822517000},"page":"324-332","source":"Crossref","is-referenced-by-count":8,"title":["Should Two-Drug Initial Therapy for Hypertension Be Recommended for All Patients?"],"prefix":"10.1007","volume":"14","author":[{"given":"Jennifer B.","family":"Cowart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Addison A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,4]]},"reference":[{"key":"280_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.HYP.0000252676.46043.18","volume":"49","author":"KL Ong","year":"2007","unstructured":"Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999\u20132004. Hypertension. 2007;49:69\u201375.","journal-title":"Hypertension"},{"key":"280_CR2","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903\u201313.","journal-title":"Lancet"},{"key":"280_CR3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1291\/hypres.28.385","volume":"28","author":"JA Staessen","year":"2005","unstructured":"Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003\u20132004 secondary prevention trials. Hypertens Res. 2005;28:385\u2013407.","journal-title":"Hypertens Res"},{"key":"280_CR4","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560\u201372.","journal-title":"JAMA"},{"key":"280_CR5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.pcad.2006.03.003","volume":"48","author":"T Rosenthal","year":"2006","unstructured":"Rosenthal T, Gavras I. Fixed-drug combinations as first-line treatment for hypertension. Prog Cardiovasc Dis. 2006;48:416\u201325.","journal-title":"Prog Cardiovasc Dis"},{"key":"280_CR6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jash.2010.02.005","volume":"4","author":"AH Gradman","year":"2010","unstructured":"\u2022\u2022 Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4:42\u201350. This position paper from the American Society of Hypertension regarding combination anti-hypertensive therapy recommended routine use of combination therapy in \u201cmost\u201d patients with hypertension.","journal-title":"J Am Soc Hypertens"},{"key":"280_CR7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","volume":"4","author":"WC Cushman","year":"2002","unstructured":"Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393\u2013404.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"280_CR8","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"\u2022\u2022 Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385. This paper reports the results of the ACCORD-BP trial, which randomized diabetic hypertensives to intense (SBP <120) versus standard (SBP <140) blood pressure control. The study did not show a difference between the two groups in CV outcomes, although a lower-than-expected event rate possibly confounded the results.","journal-title":"N Engl J Med"},{"key":"280_CR9","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1185\/03007990802262457","volume":"24","author":"JM Neutel","year":"2008","unstructured":"Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin. 2008;24:2389\u2013401.","journal-title":"Curr Med Res Opin"},{"key":"280_CR10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jash.2011.01.001","volume":"5","author":"MN Hill","year":"2011","unstructured":"Hill MN, Miller NH, Degeest S, et al. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens. 2011;5:56\u201363.","journal-title":"J Am Soc Hypertens"},{"key":"280_CR11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.HYP.0000200702.76436.4b","volume":"47","author":"EC Okonofua","year":"2006","unstructured":"Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47:345\u201351.","journal-title":"Hypertension"},{"key":"280_CR12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/HYPERTENSIONAHA.108.123455","volume":"53","author":"RD Feldman","year":"2009","unstructured":"\u2022\u2022 Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53:646\u201353. The STITCH trial randomized primary care practices to guideline care versus a simplified algorithm using fixed-dose combinations and a proscribed titration schedule. BP control was improved at 6\u00a0months in the algorithm arm compared to the guideline arm.","journal-title":"Hypertension"},{"key":"280_CR13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290\u2013300.","journal-title":"Am J Med"},{"key":"280_CR14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1524-6175.2005.04615.x","volume":"7","author":"JM Neutel","year":"2005","unstructured":"Neutel JM, Smith DH, Weber MA, et al. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: The Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) Study. J Clin Hypertens. 2005;7:641\u20136.","journal-title":"J Clin Hypertens"},{"key":"280_CR15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amjhyper.2003.08.002","volume":"17","author":"JM Neutel","year":"2004","unstructured":"Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens. 2004;17:37\u201342.","journal-title":"Am J Hypertens"},{"key":"280_CR16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427.","journal-title":"BMJ"},{"key":"280_CR17","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0002-9149(00)01199-1","volume":"86","author":"FH Messerli","year":"2000","unstructured":"Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182\u20137.","journal-title":"Am J Cardiol"},{"key":"280_CR18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.amjmed.2010.08.007","volume":"124","author":"H Makani","year":"2011","unstructured":"Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124:128\u201335.","journal-title":"Am J Med"},{"key":"280_CR19","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehr177","volume":"32","author":"PS Sever","year":"2011","unstructured":"Sever PS, Messerli FH. Hypertension management 2011: Optimal combination therapy. Eur Heart J. 2011;32:2499\u2013506.","journal-title":"Eur Heart J"},{"key":"280_CR20","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(04)16456-8","volume":"363","author":"MA Weber","year":"2004","unstructured":"Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049\u201351.","journal-title":"Lancet"},{"key":"280_CR21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2011.05.010","volume":"162","author":"JB Byrd","year":"2011","unstructured":"Byrd JB, Zeng C, Tavel HM, et al. Combination therapy as initial treatment for newly diagnosed hypertension. Am Heart J. 2011;162:340\u20136.","journal-title":"Am Heart J"},{"key":"280_CR22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.111.177592","volume":"58","author":"G Corrao","year":"2011","unstructured":"\u2022 Corrao G, Nicotra F, Parodi A, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension. 2011;58:566\u201372. This case controlled study compared initial combination antihypertensive therapy with initial monotherapy in patients without a history of CV disease. The study showed an 11\u00a0% reduction in CV events in patients started on combination therapy compared to those started on monotherapy.","journal-title":"Hypertension"},{"key":"280_CR23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/HYPERTENSIONAHA.111.178939","volume":"58","author":"TA Kotchen","year":"2011","unstructured":"Kotchen TA. Expanding role for combination drug therapy in the initial treatment of hypertension? Hypertension. 2011;58:550\u20131.","journal-title":"Hypertension"},{"key":"280_CR24","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417\u201328.","journal-title":"N Engl J Med"},{"key":"280_CR25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1751-7176.2010.00425.x","volume":"13","author":"GL Bakris","year":"2011","unstructured":"\u2022 Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13:81\u20138. This randomized controlled trial compared azilsartan with olmesartan and placebo in patients with hypertension. BP-lowering efficacy was assessed as change in baseline in mean 24-hour ambulatory systolic blood pressure. BP reduction with azilsartan was greater than with placebo; azilsartan 40\u00a0mg was non-inferior to olmesartan 40\u00a0mg, but azilsartan 80\u00a0mg reduced mean 24-hour SBP more than olmesartan 40\u00a0mg.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"280_CR26","unstructured":"Heartwire: Azilsartan\/chlorthalidone combo bests olmesartan\/HCTZ in stage 2 systolic hypertension. Available at: http:\/\/www.theheart.org\/article\/1230773.do . Accessed April 2012."},{"key":"280_CR27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"ADVANCE Collaborative Group","year":"2007","unstructured":"ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829\u201340.","journal-title":"Lancet"},{"key":"280_CR28","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","volume":"358","author":"NS Beckett","year":"2008","unstructured":"Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80\u00a0years of age or older. N Engl J Med. 2008;358:1887\u201398.","journal-title":"N Engl J Med"},{"key":"280_CR29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"PROGRESS Collaborative Study Group","year":"2001","unstructured":"PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033\u201341.","journal-title":"Lancet"},{"key":"280_CR30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1751-7176.2010.00373.x","volume":"12","author":"ME Ernst","year":"2010","unstructured":"Ernst ME, Lund BC. Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. J Clin Hypertens (Greenwich). 2010;12:927\u201334.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"280_CR31","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jacc.2010.07.053","volume":"57","author":"FH Messerli","year":"2011","unstructured":"\u2022\u2022 Messerli FH, Makani H, Benjo A, et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011;57:590\u2013600. This meta-analysis of randomized trials compared HCTZ with other anti-hypertensive agents, using ambulatory blood pressure as the outcome. HCTZ at doses of 12.5\u00a0mg and 25\u00a0mg was less effective at lowering 24-hour blood pressure than ACEIs, ARBs, \u03b2-blockers, or CCBs.","journal-title":"J Am Coll Cardiol"},{"key":"280_CR32","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.amjmed.2011.05.009","volume":"124","author":"FH Messerli","year":"2011","unstructured":"Messerli FH, Bangalore S. Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. Am J Med. 2011;124:896\u20139.","journal-title":"Am J Med"},{"key":"280_CR33","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","unstructured":"SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255\u201364.","journal-title":"JAMA"},{"key":"280_CR34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ajh.2010.1","volume":"23","author":"ME Ernst","year":"2010","unstructured":"Ernst ME, Carter BL, Zheng S, Grimm RH. Meta-analysis of dose\u2013response characteristics of hydrochlorothiazide and chlorthalidone: Effects on systolic blood pressure and potassium. Am J Hypertens. 2010;23:440\u20136.","journal-title":"Am J Hypertens"},{"key":"280_CR35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.HYP.0000103632.19915.0E","volume":"43","author":"BL Carter","year":"2004","unstructured":"Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43:4\u20139.","journal-title":"Hypertension"},{"key":"280_CR36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","volume":"47","author":"ME Ernst","year":"2006","unstructured":"Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352\u20138.","journal-title":"Hypertension"},{"key":"280_CR37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/HYPERTENSIONAHA.107.100727","volume":"51","author":"RH Fagard","year":"2008","unstructured":"Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:55\u201361.","journal-title":"Hypertension"},{"key":"280_CR38","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa022273","volume":"348","author":"DL Clement","year":"2003","unstructured":"Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407\u201315.","journal-title":"N Engl J Med"},{"key":"280_CR39","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/01.CIR.82.5.1616","volume":"82","author":"Multiple Risk Factor Intervention Trial Research Group","year":"1990","unstructured":"Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1\/2\u00a0years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616\u201328.","journal-title":"Circulation"},{"key":"280_CR40","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/HYPERTENSIONAHA.111.181248","volume":"58","author":"ME Ernst","year":"2011","unstructured":"Ernst ME, Neaton JD, Grimm Jr RH, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension. 2011;58:1001\u20137.","journal-title":"Hypertension"},{"key":"280_CR41","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/HYPERTENSIONAHA.110.161505","volume":"57","author":"MP Dorsch","year":"2011","unstructured":"Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689\u201394.","journal-title":"Hypertension"},{"key":"280_CR42","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105\u201387.","journal-title":"J Hypertens"},{"key":"280_CR43","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1161\/CIRCULATIONAHA.107.695007","volume":"117","author":"FH Messerli","year":"2008","unstructured":"Messerli FH, Bangalore S, Julius S. Risk\/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008;117:2706\u201315.","journal-title":"Circulation"},{"key":"280_CR44","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/archinte.166.20.2191","volume":"166","author":"JI Barzilay","year":"2006","unstructured":"Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166:2191\u2013201.","journal-title":"Arch Intern Med"},{"key":"280_CR45","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.HYP.0000125726.92964.ab","volume":"43","author":"P Verdecchia","year":"2004","unstructured":"Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963\u20139.","journal-title":"Hypertension"},{"key":"280_CR46","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","volume":"24","author":"HH Parving","year":"2009","unstructured":"\u2022 Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24:1663\u201371. The ALTITUDE trial is an outcomes trial in diabetics with chronic kidney disease already on an ACEI or ARB; patients were randomized to receive aliskiren or placebo. The trial was halted early (see below) due to an increase in renal impairment, stroke, hypotension, and hyperkalemia.","journal-title":"Nephrol Dial Transplant"},{"key":"280_CR47","unstructured":"Novartis. Novartis announces termination of ALTITUDE study with Rasilez\/Tekturna in high-risk patients with diabetes and renal impairment [press release]. Available at: http:\/\/www.novartis.com\/newsroom\/media-releases\/en\/2011\/1572562.shtml . Accessed April 2012."},{"key":"280_CR48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547\u201353.","journal-title":"Lancet"},{"key":"280_CR49","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547\u201359.","journal-title":"N Engl J Med"},{"key":"280_CR50","doi-asserted-by":"crossref","unstructured":"Retraction--Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2009;374:1226.","DOI":"10.1016\/S0140-6736(09)61768-2"},{"key":"280_CR51","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","volume":"27","author":"G Mancia","year":"2009","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121\u201358.","journal-title":"J Hypertens"},{"key":"280_CR52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","volume":"55","author":"AK Gupta","year":"2010","unstructured":"\u2022 Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399\u2013407. This meta-analysis analyzed trials comparing fixed-dose combinations of antihypertensive drugs with their free-drug components. There was 21\u00a0% better medication compliance, as well as non-significant trends toward fewer adverse events and better BP control, with FDCs compared to free drug components.","journal-title":"Hypertension"},{"key":"280_CR53","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","volume":"120","author":"S Bangalore","year":"2007","unstructured":"Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713\u20139.","journal-title":"Am J Med"},{"key":"280_CR54","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1751-7176.2011.00550.x","volume":"13","author":"B Sherrill","year":"2011","unstructured":"\u2022 Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898\u2013909. This meta-analysis included trials comparing fixed-dose combinations of antihypertensive drugs with their free-drug components. The analysis demonstrated lower all-cause total costs, lower hypertension- and cardiovascular-related costs, and lower medication costs with FDCs compared to free drug components.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"280_CR55","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0828-282X(07)70798-5","volume":"23","author":"NA Khan","year":"2007","unstructured":"Khan NA, Hemmelgarn B, Padwal R, et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol. 2007;23:539\u201350.","journal-title":"Can J Cardiol"},{"key":"280_CR56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11886-004-0049-0","volume":"6","author":"AA Taylor","year":"2004","unstructured":"Taylor AA. Combination drug treatment of hypertension: have we come full circle? Curr Cardiol Rep. 2004;6:421\u20136.","journal-title":"Curr Cardiol Rep"},{"key":"280_CR57","unstructured":"PDR.net: Physician\u2019s Desk Reference. Copyright 2012, PDR Network, LLC. Available at: http:\/\/www.pdr.net\/Default.aspx . Accessed April 2012."}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-012-0280-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-012-0280-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-012-0280-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:14:29Z","timestamp":1559434469000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-012-0280-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,4]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1007\/s11906-012-0280-9","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,4]]}}}